Human growth hormone (somatropin) for the treatment of growth failure in children

Human growth hormone (somatropin) for the treatment of growth failure in children (review): review decision - July 2013 information

TA188 Human growth hormone (somatropin) for the treatment of growth failure in children (review): Appendix A decision paper presented to the Institute's Guidance Executive (PDF 107 KB)

TA188 Human growth hormone (somatropin) for the treatment of growth failure in children (review): Review proposal - May 2013 information

TA188 Human growth hormone (somatropin) for the treatment of growth failure in children (review): Appendix A - provisional matrix of stakeholders (PDF 47 KB)

TA188 Human growth hormone (somatropin) for the treatment of growth failure in children (review): Appendix B - proposal paper presented to the Institute's Guidance Executive (PDF 458 KB)

Growth failure (in children) - human growth hormone (HGH) (review): final appraisal determination information

Growth failure (in children) - human growth hormone (HGH) (review): final appraisal determination (PDF 158 KB)

Response to consultee, commentator and public comments on the ACD and comments from website consultation (PDF 109 KB)

Consultee and commentator comments on the ACD

Manufacturers

Sandoz (PDF 38 KB)

Pfizer (PDF 127 KB)

Novo Nordisk (PDF 28 KB)

Merck Serono (PDF 25 KB)

Lilly (PDF 13 KB)

Ferring (PDF 28 KB)

Professional and Patient Groups

Turner Syndrome Support Society (PDF 28 KB)

Royal College of Paediatrics and Child Health (PDF 45 KB)

Royal College of Nursing (PDF 31 KB)

British Society for Paediatric Endocrinology and Diabetes (PDF 31 KB)

Other

Welsh Assembly Government (PDF 30 KB)

Commissioning Support Appraisal Service on behalf of NHS Birmingham East and North (PDF 41 KB)

Department of Health (PDF 32 KB)

Commentators

NHS Quality Improvement Scotland (PDF 10 KB)

Southampton Health Technology Assessment Centre (PDF 8.9 KB)

Web Comments (PDF 16 KB)

Professor Christopher Kelnar (PDF 9.7 KB)

Growth failure (in children) - human growth hormone (HGH) (review): appraisal consultation

Growth failure (in children) - human growth hormone (HGH) (review): appraisal consultation document information

Growth failure (in children) - human growth hormone (HGH) (review): evaluation report

Growth failure (in children) - human growth hormone (HGH) (review): overview (PDF 308 KB)

Growth failure (in children) - human growth hormone (HGH) (review): assessment report

Assessment Group Report - Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation (PDF 1.57 MB)

Assessment Group Report Addendum (PDF 133 KB)

Growth failure (in children) - human growth hormone (HGH) (review): final protocol (PDF 127 KB)

Growth failure in (children) - human growth hormone (HGH) (review): final scope (PDF 53 KB)

Growth failure in (children) - human growth hormone (HGH) (review): comments on the draft scope (PDF 723 KB)

Growth failure in (children) - human growth hormone (HGH) (review): comments on the provisional matrix (PDF 21 KB)

Growth failure (in children) - human growth hormone (HGH) (review): letter to stakeholders regarding the decision to split the scope (PDF 18 KB)

Growth failure (in children) - human growth hormone (HGH) (review): draft scope (re-issued April 2008) (PDF 62 KB)

Growth failure (in children) - human growth hormone (HGH): provisional matrix of consultees (PDF 42 KB)

Growth failure (in children) - human growth hormone (HGH): original draft scope (PDF 106 KB)

Growth failure (in children) - human growth hormone (HGH): email letter to consultees and commentators (PDF 25 KB)